Login / Signup

Real-world patient-reported outcomes and physician satisfaction with poly (ADP-ribose) polymerase inhibitors versus chemotherapy in patients with germline BRCA1/2-mutated human epidermal growth factor receptor 2-negative advanced breast cancer from the United States, Europe, and Israel.

Reshma L MahtaniAlexander NiyazovBhakti ArondekarKatie LewisAlex RiderLucy MasseyMichael Patrick Lux
Published in: BMC cancer (2022)
The PRO findings in this real-world population of patients with gBRCA1/2mut HER2- ABC complement those from the pivotal clinical trials, providing further support for treatment with PARPi in these patients.
Keyphrases